Skip to content
Screener

Boston Scientific BSX Watchman — Net Sales

Other product segments

Interventional Cardiology & Vascular Therapies
$4.64B—
Electrophysiology
$905M+24.0%
Endoscopy
$736M+9.4%
Urology
$646M+2.1%
Cardiac Rhythm Management
$578M0.0%
Neuromodulation
$318M+17.3%
Interventional Oncology & Embolization
$214M—

Similar metrics at other companies

General Mills logo
GISPet — Net Sales
$746.6M+5.8%
Amazon logo
AMZNNet product sales — Net Sales
$71.3B+11.5%
Amazon logo
AMZNNet service sales — Net Sales
$110.22B+20.2%
Wabash National logo
WNCNew trailers — Net Sales
$317.05M+1.6%
Lowe's Companies logo
LOWOther Sales — Net Sales
$551M+30.0%
Lowe's Companies logo
LOWPaint Sales — Net Sales
$1.25B+0.4%

Other financials

Income statement

See full
Revenue$5.4B+7.5%
Gross profit$3.8B+12.4%
Operating income$1.2B+43.8%
Net income$907.0M+14.1%
EPS (diluted)$0.61+15.1%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$69.46B-56.1%
P/E18.9×-44.4×
P/S3.3×-5.3×

Profitability

See full
Gross margin69.9%+1.7pp
Operating margin19.8%+2.8pp
Net margin17.5%+4.0pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity0×-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 6:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885725-26-000033
BusinessesThree Months Ended March 31, 2026 / U.S.Three Months Ended March 31, 2026 / Int'lThree Months Ended March 31, 2026 / TotalThree Months Ended March 31, 2025 / U.S.Three Months Ended March 31, 2025 / Int'lThree Months Ended March 31, 2025 / Total
Neuromodulation2368231820467271
MedSurg1,1475541,7011,0934841,577
Interventional Cardiology & Vascular Therapies5526921,2444676571,124
Watchman4624450639034425
Electrophysiology603302905511219730
Cardiac Rhythm Management349229578358220578
Interventional Oncology & Embolization1709926814287228
Cardiovascular2,1371,3663,5031,8681,2183,085

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Boston Scientific's watchman — net sales?
Boston Scientific (BSX) reported watchman — net sales of $506M in Q1 2026.
How has Boston Scientific's watchman — net sales changed year-over-year?
Boston Scientific's watchman — net sales increased by 19.1% year-over-year, from $425M to $506M.
What is the long-term trend for Boston Scientific's watchman — net sales?
Over 4 years (2021 to 2025), Boston Scientific's watchman — net sales has grown at a 24.0% compound annual growth rate (CAGR), from $829M to $1.96B.
What does watchman — net sales mean?
This metric represents the total revenue generated from the sale of left atrial appendage closure devices and related accessories. It reflects the market adoption and clinical penetration of minimally invasive technologies designed to reduce stroke risk in patients with non-valvular atrial fibrillation. As a key growth driver, this revenue stream indicates the company's competitive position within the interventional cardiology market.

Ask your AI about Boston Scientific's watchman — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude